On Wednesday, Feb. 24, the FDA said that Johnson and Johnson one-dose vaccine works well against severe COVID-19 cases. The U.S. Food and Drug Administration also stated that it could reduce the death risks of some patients.
According to The New York Times' latest report, the FDA posted its analyses online to show their Johnson and Johnson COVID-19 vaccine findings. The health agency stated that it had 72% overall efficacy against the U.S. COVID-19 variant.
On the other hand, FDA confirmed that it had 64% overall efficacy against the South African COVID-19 variant.
What FDA says regarding the vaccine's efficiency
NPR reported that FDA said that Johnson and Johnson COVID-19 vaccine has a favorable safety profile. The agency added that it will likely receive its emergency-use-authorization (EUA) approval since they see no specific safety concerns regarding the vaccine's efficiency.
Although Johnson and Johnson one-dose COVID-19 vaccine offered promising results, it is still not that effective compared to other vaccines such as Pfizer, with 95% efficacy, Moderna with 94%, and other coronavirus medicines. Since this is the case, the Johnson and Johnson vaccine developer said that they will further improve their product's performance.
"With a J&J vaccine, we'll be able to accelerate the vaccine rollout for our country and for the world," said Dan Barouch, one of Beth Israel Deaconess Medical Center's virologists.
For more news updates about Johnson and Johnson, as well as other coronavirus vaccines, always keep your tabs open here at TechTimes.
This article is owned by TechTimes.
Written by: Giuliano de Leon.